Celcuity (NASDAQ:CELC) Raised to “Hold” at Zacks Research

Celcuity (NASDAQ:CELC – Get Free Report) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

CELC has been the subject of several other research reports. Wall Street Zen raised Celcuity from a “strong sell” rating to a “sell” rating in a report on Saturday, November 14th. TD Cowen restated a “buy” rating and set a $145.00 target price on shares of Celcuity in a report on Wednesday, October 21st. Royal Bank Of Canada downgraded shares of Celcuity to a “neutral” rating in a report on Wednesday, October 28th. HC Wainwright dropped their price target on shares of Celcuity from $155.00 to $150.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $177.00 price target on shares of Celcuity in a research note on Monday, August 17th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $151.79.

Check Out Our Latest Research Report on Celcuity

Celcuity Stock Performance

CELC opened at $55.60 on Tuesday. The business’s 50-day simple moving average is $70.38 and its 200 day simple moving average is $97.42. Celcuity has a 52-week low of $53.54 and a 52-week high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 14.59 and a current ratio of 14.62. The firm has a market capitalization of $2.73 billion, a PE ratio of -11.80 and a beta of 0.16.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.30. As a group, sell-side analysts expect that Celcuity will post -5.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several large investors have recently modified their holdings of the stock. Parallel Advisors LLC bought a new stake in shares of Celcuity during the 1st quarter worth about $38,000. PNC Financial Services Group Inc. grew its stake in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after buying an additional 86 shares during the last quarter. KBC Group NV bought a new position in Celcuity in the 1st quarter valued at about $64,000. IFP Advisors Inc bought a new position in Celcuity in the 2nd quarter valued at about $73,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Celcuity by 139.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock valued at $94,000 after acquiring an additional 477 shares during the period. 63.33% of the stock is owned by institutional investors.

Latest Celcuity News

Investors following CELC have been watching these news items:

  • Positive Sentiment: HC Wainwright kept its Buy rating and $150 price target. It also modestly improved its Q3 2027 EPS estimate to a loss of $0.73 per share from a loss of $0.80. MarketBeat coverage
  • Negative Sentiment: The larger revisions were downward: HC Wainwright now expects a 2026 loss of $5.23 per share, versus $4.84 previously, and a 2027 loss of $3.87, versus $3.10. It also raised projected losses for Q4 2026 and each of the first, second, and fourth quarters of 2027.
  • Negative Sentiment: Longer-term earnings expectations were cut substantially: the 2028 forecast shifted from $0.92 profit to a $1.38 loss; 2029 profit was reduced from $3.78 to $1.32 per share; and 2030 profit was lowered from $7.21 to $4.00. These changes suggest a slower path to profitability and are the clearest potential headwind for CELC. MarketBeat coverage

About Celcuity

(Get Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Further Reading

Analyst Recommendations for Celcuity (NASDAQ:CELC)

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.